RBC Capital Markets analyst Leonid Timashev increased the price target for Axsome Therapeutics (NASDAQ:AXSM) to $143 from $139, while keeping an Outperform rating on the stock. According to ...

Markets sold off on Monday as investors digested Donald Trump's tariff announcements on Mexico, Canada and China.

RBC Capital Markets increased its price target on Celestica (NYSE:CLS) shares from $115.00 to $140.00 while maintaining an Outperform rating. Currently trading at $131.66, near its 52-week high, ...

In a report released today, Nik Modi from RBC Capital reiterated a Hold rating on Colgate-Palmolive (CL – Research Report), with a price target ...

RBC Capital analyst Kenneth Lee maintained a Buy rating on OneMain Holdings (OMF – Research Report) yesterday and set a price target of $65.00.

Bonnici was a managing director at RBC and led several high-profile deals across infrastructure and technology during his ...

J.M. Smucker Co. chief executive Mark Smucker leaned on close advisers when he made the decision to bolster the jelly and ...

Investing.com -- RBC Capital Markets on Monday upgraded Carvana (NYSE:CVNA) shares to Outperform, and lifted the target price to $280 from $270. According to the firm’s analysts, following ...

Each year, RBC supports thousands of students from different educational backgrounds in exploring various career paths within ...

Investing.com -- RBC Capital Markets lowered its price target for Nike Inc (NYSE:NKE) to $70 from $80 on the prolonged challenges in the company’s turnaround efforts. While the brokerage ...

Find insight on United Utilities, Viva Energy, Valero Energy and more in the latest Market Talks covering Energy and ...

The downgrade comes after the company reported full-year revenue that fell 4% below market expectations, reflecting an underperformance in the second half of the year.